{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:27:18Z","timestamp":1761514038419},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s12072-017-9807-0","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T01:01:33Z","timestamp":1499821293000},"page":"56-67","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of etiological treatment on prognosis"],"prefix":"10.1007","volume":"12","author":[{"given":"Chien-Wei","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,12]]},"reference":[{"key":"9807_CR1","doi-asserted-by":"crossref","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749\u20131761","DOI":"10.1016\/S0140-6736(14)60121-5"},{"key":"9807_CR2","doi-asserted-by":"crossref","unstructured":"Allampati S, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2016;20:551\u2013562","DOI":"10.1016\/j.cld.2016.02.011"},{"key":"9807_CR3","doi-asserted-by":"crossref","unstructured":"Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386:1565\u20131575","DOI":"10.1016\/S0140-6736(15)00154-3"},{"key":"9807_CR4","doi-asserted-by":"crossref","unstructured":"Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011;55:171\u2013182","DOI":"10.1016\/j.jhep.2010.12.012"},{"key":"9807_CR5","doi-asserted-by":"crossref","unstructured":"Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis 2015;19:187\u2013198","DOI":"10.1016\/j.cld.2014.09.011"},{"key":"9807_CR6","doi-asserted-by":"crossref","unstructured":"Calvaruso V, Craxi A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int 2014;34(Suppl 1):85\u201390","DOI":"10.1111\/liv.12395"},{"key":"9807_CR7","doi-asserted-by":"crossref","unstructured":"Corey KE, Rinella ME. Medical and surgical treatment options for nonalcoholic steatohepatitis. Dig Dis Sci 2016;61:1387\u20131397","DOI":"10.1007\/s10620-016-4083-8"},{"key":"9807_CR8","doi-asserted-by":"crossref","unstructured":"Wallace J, Pitts M, Locarnini S, Ellard J, Carman M, Chen DS. Essential components in developing public policy to control viral hepatitis: lessons from Taiwan. Hepatol Int 2016;10:355\u2013362","DOI":"10.1007\/s12072-015-9660-y"},{"key":"9807_CR9","doi-asserted-by":"crossref","unstructured":"Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012;57:730\u2013735","DOI":"10.1016\/j.jhep.2012.05.021"},{"key":"9807_CR10","doi-asserted-by":"crossref","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1\u201398","DOI":"10.1007\/s12072-015-9675-4"},{"key":"9807_CR11","doi-asserted-by":"crossref","unstructured":"Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 2015;62:S76\u2013S86","DOI":"10.1016\/j.jhep.2015.01.018"},{"key":"9807_CR12","doi-asserted-by":"crossref","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095\u20132128","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"9807_CR13","doi-asserted-by":"crossref","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65\u201373","DOI":"10.1001\/jama.295.1.65"},{"key":"9807_CR14","doi-asserted-by":"crossref","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678\u2013686","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"9807_CR15","doi-asserted-by":"crossref","unstructured":"Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis 2016;20:645\u2013665","DOI":"10.1016\/j.cld.2016.06.002"},{"key":"9807_CR16","doi-asserted-by":"crossref","unstructured":"Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206\u20131217","DOI":"10.1056\/NEJMoa040431"},{"key":"9807_CR17","doi-asserted-by":"crossref","unstructured":"Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660\u20131667","DOI":"10.1053\/gast.1997.v113.pm9352870"},{"key":"9807_CR18","doi-asserted-by":"crossref","unstructured":"Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45\u201352","DOI":"10.1016\/j.jhep.2006.08.021"},{"key":"9807_CR19","doi-asserted-by":"crossref","unstructured":"Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 2010;32:1059\u20131068","DOI":"10.1111\/j.1365-2036.2010.04447.x"},{"key":"9807_CR20","doi-asserted-by":"crossref","unstructured":"Sung JJY, Tsoi KKF, Wong VWS, Li KCT, Chan HLY. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharm Ther 2008;28:1067\u20131077","DOI":"10.1111\/j.1365-2036.2008.03816.x"},{"key":"9807_CR21","doi-asserted-by":"crossref","unstructured":"Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009;16:265\u2013271","DOI":"10.1111\/j.1365-2893.2009.01070.x"},{"key":"9807_CR22","doi-asserted-by":"crossref","unstructured":"Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 2016;213:966\u2013974","DOI":"10.1093\/infdis\/jiv547"},{"key":"9807_CR23","doi-asserted-by":"crossref","unstructured":"Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014;60:1127\u20131134","DOI":"10.1016\/j.jhep.2014.02.013"},{"key":"9807_CR24","doi-asserted-by":"crossref","unstructured":"Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015;60:1457\u20131464","DOI":"10.1007\/s10620-014-3486-7"},{"key":"9807_CR25","doi-asserted-by":"crossref","unstructured":"Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016;43:134\u2013144","DOI":"10.1111\/apt.13440"},{"key":"9807_CR26","doi-asserted-by":"crossref","unstructured":"Watanabe T, Tokumoto Y, Joko K, Michitaka K, Mashiba T, Hiraoka A, et al. Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hepatol Int 2016;10:320\u2013327","DOI":"10.1007\/s12072-015-9647-8"},{"key":"9807_CR27","doi-asserted-by":"crossref","unstructured":"Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886\u2013893","DOI":"10.1002\/hep.23785"},{"key":"9807_CR28","doi-asserted-by":"crossref","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468\u2013475","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"9807_CR29","doi-asserted-by":"crossref","unstructured":"Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol 2009;51:468\u2013474","DOI":"10.1016\/j.jhep.2009.05.031"},{"key":"9807_CR30","doi-asserted-by":"crossref","unstructured":"Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521\u20131531","DOI":"10.1056\/NEJMoa033364"},{"key":"9807_CR31","doi-asserted-by":"crossref","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593\u20131608","DOI":"10.1053\/j.gastro.2009.08.063"},{"key":"9807_CR32","doi-asserted-by":"crossref","unstructured":"Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. J Gastroenterol Hepatol 2013;28:1849\u20131858","DOI":"10.1111\/jgh.12283"},{"key":"9807_CR33","doi-asserted-by":"crossref","unstructured":"Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121\u2013129","DOI":"10.1002\/hep.20760"},{"key":"9807_CR34","doi-asserted-by":"crossref","unstructured":"Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574\u2013593","DOI":"10.1007\/s12072-016-9720-y"},{"key":"9807_CR35","doi-asserted-by":"crossref","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537\u20131547","DOI":"10.1002\/hep.26301"},{"key":"9807_CR36","doi-asserted-by":"crossref","unstructured":"Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014;109:1223\u20131233","DOI":"10.1038\/ajg.2014.145"},{"key":"9807_CR37","doi-asserted-by":"crossref","unstructured":"Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36:1755\u20131764","DOI":"10.1111\/liv.13253"},{"key":"9807_CR38","doi-asserted-by":"crossref","unstructured":"Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015;9:243\u2013250","DOI":"10.1007\/s12072-015-9614-4"},{"key":"9807_CR39","doi-asserted-by":"crossref","unstructured":"Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176\u2013182","DOI":"10.1016\/j.jhep.2009.11.007"},{"key":"9807_CR40","doi-asserted-by":"crossref","unstructured":"Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014;147:143\u2013151","DOI":"10.1053\/j.gastro.2014.03.048"},{"key":"9807_CR41","doi-asserted-by":"crossref","unstructured":"Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363\u2013370","DOI":"10.1016\/j.jhep.2014.08.045"},{"key":"9807_CR42","doi-asserted-by":"crossref","unstructured":"Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int 2016;10:277\u2013285","DOI":"10.1007\/s12072-015-9661-x"},{"key":"9807_CR43","doi-asserted-by":"crossref","unstructured":"Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702\u2013726","DOI":"10.1007\/s12072-016-9717-6"},{"key":"9807_CR44","doi-asserted-by":"crossref","unstructured":"Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39:333\u2013342","DOI":"10.1002\/hep.20073"},{"key":"9807_CR45","doi-asserted-by":"crossref","unstructured":"Hezode C, Castera L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011;34:656\u2013663","DOI":"10.1111\/j.1365-2036.2011.04765.x"},{"key":"9807_CR46","doi-asserted-by":"crossref","unstructured":"Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006;101:2269\u20132274","DOI":"10.1111\/j.1572-0241.2006.00743.x"},{"key":"9807_CR47","doi-asserted-by":"crossref","unstructured":"Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 2015;62:355\u2013364","DOI":"10.1002\/hep.27766"},{"key":"9807_CR48","doi-asserted-by":"crossref","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584\u20132593","DOI":"10.1001\/jama.2012.144878"},{"key":"9807_CR49","doi-asserted-by":"crossref","unstructured":"Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142\u2013156","DOI":"10.1053\/j.gastro.2016.09.009"},{"key":"9807_CR50","doi-asserted-by":"crossref","unstructured":"Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 2016;151:130\u2013139","DOI":"10.1053\/j.gastro.2016.03.036"},{"key":"9807_CR51","doi-asserted-by":"crossref","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618\u20132628","DOI":"10.1056\/NEJMoa1512614"},{"key":"9807_CR52","doi-asserted-by":"crossref","unstructured":"Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493\u20131505","DOI":"10.1002\/hep.28446"},{"key":"9807_CR53","doi-asserted-by":"crossref","unstructured":"Foster GR, Irving WL, Cheung MCM, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;63:1224\u20131231","DOI":"10.1016\/j.jhep.2016.01.029"},{"key":"9807_CR54","doi-asserted-by":"crossref","unstructured":"Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692\u2013699","DOI":"10.1016\/j.jhep.2016.05.027"},{"key":"9807_CR55","doi-asserted-by":"crossref","unstructured":"Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741\u2013747","DOI":"10.1016\/j.jhep.2016.06.019"},{"key":"9807_CR56","doi-asserted-by":"crossref","unstructured":"Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719\u2013726","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"9807_CR57","doi-asserted-by":"crossref","unstructured":"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727\u2013733","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"9807_CR58","doi-asserted-by":"crossref","unstructured":"Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643\u20133650","DOI":"10.1200\/JCO.2011.36.2335"},{"key":"9807_CR59","doi-asserted-by":"crossref","unstructured":"Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C\/hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology 2009;136:496\u2013504","DOI":"10.1053\/j.gastro.2008.10.049"},{"key":"9807_CR60","doi-asserted-by":"crossref","unstructured":"Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 2013;57:2135\u20132142","DOI":"10.1002\/hep.26266"},{"key":"9807_CR61","doi-asserted-by":"crossref","unstructured":"Londono MC, Lens S, Marino Z, Bonacci M, Ariza X, Broquetas T, et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon0free regimen. Aliment Pharmacol Ther 2017;45:1156\u20131161","DOI":"10.1111\/apt.13985"},{"key":"9807_CR62","doi-asserted-by":"crossref","unstructured":"Ozaras R, Sunbul M, parlak M, Bodur H, Leblebicioglu H. Treating hepatitis B virus\/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe. Hepatology 2016;64:1825\u20131827","DOI":"10.1002\/hep.28592"},{"key":"9807_CR63","doi-asserted-by":"crossref","unstructured":"Rehm L, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223\u20132233","DOI":"10.1016\/S0140-6736(09)60746-7"},{"key":"9807_CR64","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399\u2013420","DOI":"10.1016\/j.jhep.2012.04.004"},{"key":"9807_CR65","doi-asserted-by":"crossref","unstructured":"Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol 2015;62:S38\u2013S46","DOI":"10.1016\/j.jhep.2015.03.006"},{"key":"9807_CR66","doi-asserted-by":"crossref","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758\u20132769","DOI":"10.1056\/NEJMra0805786"},{"key":"9807_CR67","doi-asserted-by":"crossref","unstructured":"Teli MRDC, Burt AD, Bennett MK, James OF, Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346:987\u2013990","DOI":"10.1016\/S0140-6736(95)91685-7"},{"key":"9807_CR68","doi-asserted-by":"crossref","unstructured":"Thursz M, Morgan TR. Treatment of severe alcoholic hepatitis. Gastroenterology 2016;150:1823\u20131834","DOI":"10.1053\/j.gastro.2016.02.074"},{"key":"9807_CR69","doi-asserted-by":"crossref","unstructured":"Mathurin P, Beuzin F, Louvet A, Carrie-Ganne N, Balian A, Trichet JC, et al. Fibrosis preogression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther 2007;25:1047\u20131054","DOI":"10.1111\/j.1365-2036.2007.03302.x"},{"key":"9807_CR70","doi-asserted-by":"crossref","unstructured":"Adams R, Karam V, Delvart V, O\u2019Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57:675\u2013688","DOI":"10.1016\/j.jhep.2012.04.015"},{"key":"9807_CR71","doi-asserted-by":"crossref","unstructured":"Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN\/SRTR 2013 Annual Data Report: Liver. Am J Transplant 2015;15 Suppl 2:1\u201328","DOI":"10.1111\/ajt.13197"},{"key":"9807_CR72","doi-asserted-by":"crossref","unstructured":"Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs. without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013;310:1033\u20131041","DOI":"10.1001\/jama.2013.276300"},{"key":"9807_CR73","doi-asserted-by":"crossref","unstructured":"Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372:1619\u20131628","DOI":"10.1056\/NEJMoa1412278"},{"key":"9807_CR74","doi-asserted-by":"crossref","unstructured":"Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193\u2013199","DOI":"10.1016\/0016-5085(78)90401-8"},{"key":"9807_CR75","doi-asserted-by":"crossref","unstructured":"O\u2019Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. AASLD practice guidelines: alcoholic liver disease. Hepatology 2010;51:307\u2013328","DOI":"10.1002\/hep.23258"},{"key":"9807_CR76","doi-asserted-by":"crossref","unstructured":"Forrest EH, Evans CD, Stewatt S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and deviation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174\u20131179","DOI":"10.1136\/gut.2004.050781"},{"key":"9807_CR77","doi-asserted-by":"crossref","unstructured":"Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;103:2747\u20132756","DOI":"10.1111\/j.1572-0241.2008.02104.x"},{"key":"9807_CR78","doi-asserted-by":"crossref","unstructured":"Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348\u20131354","DOI":"10.1002\/hep.21607"},{"key":"9807_CR79","doi-asserted-by":"crossref","unstructured":"Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O\u2019Grady J, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterology 2015;149:398\u2013406","DOI":"10.1053\/j.gastro.2015.04.044"},{"key":"9807_CR80","doi-asserted-by":"crossref","unstructured":"Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007;46:827\u2013839","DOI":"10.1016\/j.jhep.2007.01.025"},{"key":"9807_CR81","doi-asserted-by":"crossref","unstructured":"Luca A, Garcia-Pagan JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997;112:1284\u20131289","DOI":"10.1016\/S0016-5085(97)70142-2"},{"key":"9807_CR82","doi-asserted-by":"crossref","unstructured":"Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014;20:2143\u20132158","DOI":"10.3748\/wjg.v20.i9.2143"},{"key":"9807_CR83","unstructured":"Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res health 2003;27:209\u2013219"},{"key":"9807_CR84","doi-asserted-by":"crossref","unstructured":"Pessione F, Ramond MJ, peters L, Pham BN, Batel P, Rueff B, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effects of alcoholic hepatitis, smoking and abstinence. Liver Int 2003;23:45\u201353","DOI":"10.1034\/j.1600-0676.2003.01804.x"},{"key":"9807_CR85","doi-asserted-by":"crossref","unstructured":"Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986;256:1449\u20131455","DOI":"10.1001\/jama.1986.03380110055026"},{"key":"9807_CR86","doi-asserted-by":"crossref","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915\u20131922","DOI":"10.1016\/S0140-6736(07)61814-5"},{"key":"9807_CR87","doi-asserted-by":"crossref","unstructured":"Xie YD, Feng B, Gao Y, Wei L. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systemic review and meta-analysis. Hepatol Res 2014;44:436\u2013449","DOI":"10.1111\/hepr.12131"},{"key":"9807_CR88","doi-asserted-by":"crossref","unstructured":"Farooq MO, Bataller R. Pathogenesis and management of alcoholic liver disease. Dig Dis 2016;34:347\u2013355","DOI":"10.1159\/000444545"},{"key":"9807_CR89","doi-asserted-by":"crossref","unstructured":"Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systemic review and network meta-analysis. Gastroenterology 2015;149:958\u2013970","DOI":"10.1053\/j.gastro.2015.06.006"},{"key":"9807_CR90","doi-asserted-by":"crossref","unstructured":"Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480\u2013487","DOI":"10.1016\/S0168-8278(01)00289-6"},{"key":"9807_CR91","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systemic review: glucocorticosteroids for alcoholic hepatitis\u2014a Cochrane Hepato-Biliary Group systemic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27:1167\u20131178","DOI":"10.1111\/j.1365-2036.2008.03685.x"},{"key":"9807_CR92","doi-asserted-by":"crossref","unstructured":"Mathurin P, O\u2019Grady J, Carithers RL, Philips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255\u2013260","DOI":"10.1136\/gut.2010.224097"},{"key":"9807_CR93","doi-asserted-by":"crossref","unstructured":"Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637\u20131648","DOI":"10.1053\/gast.2000.20189"},{"key":"9807_CR94","doi-asserted-by":"crossref","unstructured":"Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systemic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;37:845\u2013854","DOI":"10.1111\/apt.12279"},{"key":"9807_CR95","doi-asserted-by":"crossref","unstructured":"Moreno C, Langlet P, Hittelet A, Lasser L, Degre D, Evrard S, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010;53:1117\u20131122","DOI":"10.1016\/j.jhep.2010.05.030"},{"key":"9807_CR96","doi-asserted-by":"crossref","unstructured":"Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365:1781\u20131789","DOI":"10.1056\/NEJMoa1101214"},{"key":"9807_CR97","doi-asserted-by":"crossref","unstructured":"Goldber D, Ditah IC, Saeian K, lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017;152:1090\u20131099","DOI":"10.1053\/j.gastro.2017.01.003"},{"key":"9807_CR98","doi-asserted-by":"crossref","unstructured":"Dumortier J, Dharancy S, Cannesson A, Lassailly G, Rolland B, Pruvot FR, et al. Recurrence alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. Am J Gastroenterol 2015;110:1160\u20131166","DOI":"10.1038\/ajg.2015.204"},{"key":"9807_CR99","doi-asserted-by":"crossref","unstructured":"Ursic-Bedoya J, Faure S, Donnadieu-Rigole H, Pageaux GP. Liver transplantation for alcoholic liver disease: lessions learned and unresolved issues. World J Gastroenterol 2015;21:10994\u201311002","DOI":"10.3748\/wjg.v21.i39.10994"},{"key":"9807_CR100","doi-asserted-by":"crossref","unstructured":"Erard-Poinsot D, Guillaud O, Hervieu V, Thimonier E, Vallin M, Chambon-Augoyard C, et al. Severe alcoholic relapse after liver transplantation: what consequences on the graft? A study based on liver biopsies analysis. Liver Transplantation 2016;22:773\u2013784","DOI":"10.1002\/lt.24425"},{"key":"9807_CR101","doi-asserted-by":"crossref","unstructured":"Duvoux C, Delacroix I, Richardet JP, Roudot-Thoraval F, Metreau JM, Fagniez PL, et al. Increased incidence of oropharyngeal squamous cell carcinoma after liver transplantation for alcoholic cirrhosis. Transplantation 1999;67:418\u2013421","DOI":"10.1097\/00007890-199902150-00014"},{"key":"9807_CR102","doi-asserted-by":"crossref","unstructured":"Novo-Veleiro I, Calle CDL, Dominguez-Quiben S, Pastor I, Marcos M, Laso FJ. Prevalence of hepatitis C virus infection in alcoholic patients: cohort study and systemic review. Alcohol Alcohol 2013:48:564\u2013569","DOI":"10.1093\/alcalc\/agt044"},{"key":"9807_CR103","doi-asserted-by":"crossref","unstructured":"Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006;30:709\u2013719","DOI":"10.1111\/j.1530-0277.2006.00083.x"},{"key":"9807_CR104","doi-asserted-by":"crossref","unstructured":"Zhang T, Li Y, Lai JP, Douglas SD, Metzger DS, O\u2019Brien CP. Ho WZ. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003;38:57\u201365","DOI":"10.1053\/jhep.2003.50295"},{"key":"9807_CR105","doi-asserted-by":"crossref","unstructured":"Sebastiani G, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hepat 2006;13:199\u2013205","DOI":"10.1111\/j.1365-2893.2005.00662.x"},{"key":"9807_CR106","doi-asserted-by":"crossref","unstructured":"Amand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al. VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006;130:1607\u20131616","DOI":"10.1053\/j.gastro.2006.02.023"},{"key":"9807_CR107","doi-asserted-by":"crossref","unstructured":"Tsui JI, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006;44:262\u2013266","DOI":"10.1016\/j.jhep.2005.07.027"},{"key":"9807_CR108","doi-asserted-by":"crossref","unstructured":"Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol 2013;58:730\u2013735","DOI":"10.1016\/j.jhep.2012.11.045"},{"key":"9807_CR109","doi-asserted-by":"crossref","unstructured":"Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY, et al. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2013;7:645\u2013654","DOI":"10.1007\/s12072-012-9375-2"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-017-9807-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T12:46:40Z","timestamp":1569761200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-017-9807-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,12]]},"references-count":109,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["9807"],"URL":"https:\/\/doi.org\/10.1007\/s12072-017-9807-0","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,12]]}}}